Today, FDA released the Long-Term National Strategy to Increase the Resiliency of the U.S. Infant Formula Market, which outlines long-term actions to improve information-sharing across all interested parties, as well as building on actions taken since 2023, to help protect the integrity of the infant formula supply chain. The long-term strategy also addresses implementing measures for preventing contamination, incentivizing new infant formula manufacturers to enter the U.S. market, and authorities needed to gain better insight into the supply chain and risk for shortages. The FDA is committed to working with all interested parties to improve the resiliency of the infant formula supply and to ensure that consumers have the utmost confidence that the infant formula available in the U.S. is safe and nutritious. The National Academies of Sciences, Engineering, and Medicine has partnered with the FDA to study challenges of the to the infant formula market in the U.S. https://lnkd.in/ecDmDUNc
About us
The Food and Drug Administration is an agency within the Department of Health and Human Services. The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. FDA also plays a significant role in the Nation's counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to respond to deliberate and naturally emerging public health threats.
- Website
-
http://www.fda.gov/
External link for FDA
- Industry
- Government Administration
- Company size
- 10,001+ employees
- Headquarters
- Silver Spring, MD
- Type
- Government Agency
- Specialties
- Food, Drugs, Medical Devices, Vaccines Blood and Biologics, Animal and Veterinary, Cosmetics, Radiation-Emitting Products, Tobacco Products, Regulatory Research, and Toxicological Regulatory Research
Locations
-
Primary
10903 New Hampshire Ave
Silver Spring, MD 20993, US
Employees at FDA
Updates
-
Attention healthcare providers! Staying informed about the latest in the pharmaceutical landscape is crucial for delivering optimal patient care. The FDA's Purple Book is a comprehensive guide to licensed biological products and the go-to source for information on biosimilars, interchangeable biosimilars, and their reference products. Access this comprehensive resource here: https://lnkd.in/eRpc-mhD #PurpleBook
-
FDA has issued draft guidance to help manufacturers and processors of Low Moisture Ready-to-Eat (LMRTE) human foods, including powdered infant formula, comply with requirements for current good manufacturing practices, hazard analysis, and risk-based preventive controls to ensure a safe and sanitary food supply. https://lnkd.in/eKE_Vzhm
Draft Guidance for Industry: LMTRE
fda.gov
-
Today, the U.S. Food and Drug Administration, U.S. Homeland Security Investigations, and U.S. Customs and Border Protection announced the seizure of more than 628,000 unauthorized e-cigarette products from a warehouse in Miami. The seized products—mostly flavored, disposable e-cigarettes as well as some packs, kits, and batteries—were valued at more than $7 million and included some brands that may appeal to youth, such as Geek Bar. https://lnkd.in/d8x8yqhb
-
Join Boris Jiron from the Office of Digital Transformation (ODT) as he discusses how his role in ODT helps support FDA’s mission to protect public health. ODT professionals like Boris collaborate across multiple disciplines to help develop innovative digital solutions that help streamline FDA operations. Watch the video to learn more about ODT staff roles, culture, and how ODT is at the forefront of digital transformation! Interested in a challenging career at the intersection of technology and public health? Visit ODT’s Career page to view current job opportunities, send your resume for inclusion in our resume bank, sign up for job alerts, and more: https://lnkd.in/ezCARPmw #OneODT
-
📣Today’s the day! Join us at 5:00 PM EST today for the precisionFDA Generative AI (GenAI) Community Challenge: Democratizing and Demystifying AI. The latest challenge, hosted by FDA’s Office of Digital Transformation, invites participants to dive deep into the strengths and limitations of GenAI applications when applied to guidance documents. Submissions for the Challenge will be accepted through February 28, 2025. Like, comment, and spread the word by sharing this opportunity with those in your network who may be interested in this crowdsourcing Challenge. 🔎Learn more about the latest precisionFDA Challenge: https://lnkd.in/gteCtXTK 🔎Learn more about precisionFDA: https://precision.fda.gov/ 🔎Read FDA’s IT Strategy to learn how the agency is leveraging emerging data and technology to safeguard and improve public health: https://lnkd.in/gMis_6RR
-
Join us for the BsUFA III Regulatory Science Pilot Program Progress Update webinar! 📅 Date: January 22, 2025 ⏰ Time: 1 PM – 2 PM EST Learn how FDA is advancing biosimilar development through innovative science, streamlining development processes, and enhancing access to affordable treatments. This session will provide updates on the program’s achievements and next steps. 💡 Don’t miss this opportunity to hear from FDA experts. 👉 Register today: https://bit.ly/4eOs9n4
BsUFA III Regulatory Science Pilot Program: Progress Update
fda.gov
-
FDA celebrates the life of President Jimmy Carter and his commitment to public health. President Carter signed the Infant Formula Act into law on Sept. 26, 1980. In the ceremony pictured here, he said that the law was "designed to ensure that commercially produced and marketed infant formulas meet accepted nutritional standards and that consistent quality is maintained in their preparation."
-
FDA Oncology Center's Jennifer G. and AACR President Dr. Patricia M. LoRusso will moderate an FDA-American Association for Cancer Research workshop January 16 exploring the considerations surrounding pharmacogenetic testing for dihydropyrimidine dehydrogenase (DPD) deficiency. Register now for in person or virtual attendance: https://lnkd.in/eNNX4NFS
-
Just out! The 2024 New Drug Therapy Approvals report – it includes approvals for therapies that collectively treat a wide range of conditions, including a first-in-class drug for schizophrenia, three novel antibiotics and new drugs for many types of cancer. https://lnkd.in/eVUZCxPi #FDAVoices